Free Newsletter
MES upgrade tactic: Slay the tweak dragon
Process data are becoming as important as the product itself in drug manufacturing, says the lead engineer on a multi-site implementation of a manufacturing execution system--no process documentation, no product release. So Hoffmann-La Roche is automating across eight sites using the Rockwell Automation MES Core.
Batch data-collection methods pale in comparison to those of an MES, reflecting the current regulatory expectation for mastery of not just process but also process measurement. There's a corporate mandate, too, for greater global operational consistency. The means for serving both masters are centralized best practices and error reduction--all for the end of "significant cost savings," says Robert Fretz in a trade magazine interview.
Fretz, who heads up the MES program as part of Roche's Pharma Global Engineering group, says the centralized approach lets him collect experiences and best practices from all sites into one system, for the benefit of all. It also aligns business processes to uniform compliance and efficiency standards.
One of his key implementation tactics is to keep customization to a minimum. "Although we are challenged to reach less than 10% customizations by the different type of site operations (solids, parenterals, packaging), having too many customizations will lead to being stuck with an older version [of the MES] as costs for upgrades are getting prohibitively high," says Fretz.
- read the interview
Related Articles:
Presto! Tamiflu multiplies in supply chain magic
Mobile system tracks assets
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: